ABVX on Nasdaq

Abivax S.A.

Price unavailable

Last updated Oct 16, 2026.

Overview

-336.1MNet income, fiscal 20252

Compare with another stock.

  • TickerABVX on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersI0
  • Incorporated inFrance3
  • Business address7 Bd Haussmann, Paris3
  • Filer categoryAccelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-73.8%Return on equity2
-$161.3MFree cash flow2

Financial statements

Operating income452-$246.1M in 2025+494% since 2021
-$300.0M-$200.0M-$100.0M02021: -$41.4M-$41.4M20212022: -$64.8M-$64.8M2022+57%2023: -$127.4M-$127.4M2023+96%2024: -$173.0M-$173.0M2024+36%2025: -$246.1M-$246.1M2025+42%
Net income452-$336.1M in 2025+692% since 2021
-$400.0M-$300.0M-$200.0M-$100.0M02021: -$42.5M-$42.5M20212022: -$60.7M-$60.7M2022+43%2023: -$147.7M-$147.7M2023+143%2024: -$176.2M-$176.2M2024+19%2025: -$336.1M-$336.1M2025+91%

Every line of the income statement in the latest annual report, as filed.2

Period ending2025-12-312024-12-312023-12-31
Other operating income4.6M EUR12.4M EUR4.6M EUR
Total operating income4.6M EUR12.4M EUR4.6M EUR
Sales and marketing-5.2M EUR-6.0M EUR-6.4M EUR
Research and development-177.8M EUR-146.5M EUR-103.2M EUR
General and administrative-67.7M EUR-32.9M EUR-22.4M EUR
Total operating expenses-250.6M EUR-185.4M EUR-132.0M EUR
Operating loss-246.1M EUR-173.0M EUR-127.4M EUR
Financial expenses-111.7M EUR-17.0M EUR-27.9M EUR
Financial income27.5M EUR13.7M EUR7.5M EUR
Financial gain (loss)-84.2M EUR-3.3M EUR-20.4M EUR
Net loss before tax-330.3M EUR-176.2M EUR-147.7M EUR
Income tax-5.8M EUR0 EUR0 EUR
Net loss for the period-336.1M EUR-176.2M EUR-147.7M EUR
Weighted average number of outstanding shares used for computing basic loss per share (in shares)69.5M shares63.0M shares43.1M shares
Weighted average number of outstanding shares used for computing diluted loss per share (in shares)69.5M shares63.0M shares43.1M shares
Basic loss per share (in euro per share)-4.83 EUR-2.80 EUR-3.43 EUR
Diluted loss per share (in euro per share)-4.83 EUR-2.80 EUR-3.43 EUR

Compare Abivax S.A. with another company

Recent filings

  1. Sep 21, 20266-K
  2. Sep 21, 2026F-6EF
  3. Aug 14, 2026SCHEDULE 13G/A
  4. Aug 13, 2026SCHEDULE 13G/A
  5. Jul 6, 2026SCHEDULE 13D/A
  6. Jul 2, 2026424B5
  7. Jul 2, 20266-K
  8. Jul 1, 2026FWP
  9. Jun 30, 2026POSASR
  10. Jun 30, 2026424B5
  11. Jun 30, 2026FWP
  12. Jun 29, 20266-K
  13. Jun 2, 20266-K
  14. May 22, 20266-K
  15. May 20, 20266-K

Every filing from the last three years, summarized. The full record is on SEC EDGAR.1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5